Oya, Junko http://orcid.org/0000-0002-6413-2606
Nakagami, Tomoko
Hasegawa, Yukiko
Kondo, Yuichiro
Katamine, Aki
Shimizu, Mika
Kubota, Ryo
Suda, Rika
Babazono, Tetsuya
Article History
Received: 7 June 2023
Accepted: 29 November 2023
First Online: 8 January 2024
Declarations
:
: T Babazono has received honoraria for lectures from Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co. Ltd., Sanofi K.K., Novo Nordisk Pharma Ltd., Sumitomo Pharma Co. Ltd., Sanwa Kagaku Kenkyusyo Co. Ltd.; has received research support from Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Women’s Health Japan K.K.; and has received grants from Sanwa Kagaku Kenkyusyo Co. Ltd., Sumitomo Pharma Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Abbott Japan LLC. T Nakagami reported personal fee from Sanwa Kagaku Kenkyusho Co Ltd, Novo Nordisk Pharma Ltd Japan, Eli Lily Japan KK, Sanofi K.K., Sumitomo Pharma, and Boehringer Ingelheim Japan Inc. Other authors declare that they have no conflict interest.
: The study was approved by the Ethics Review Committee of Tokyo Women’s Medical University (Approval no. 2481-R3, November 18, 2022). All clinical investigations were conducted in accordance with the tenets of the Declaration of Helsinki.
: Because of the retrospective observational design, written informed consent was not obtained from the participants, although it was obtained via the opt-out method through the website of the institution.